Clinical Trial Detail

NCT ID NCT03174197
Title Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

glioblastoma multiforme

malignant glioma

gliosarcoma

Therapies

Atezolizumab + Temozolomide

Age Groups: adult senior

No variant requirements are available.